ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Codexis Doses First Subjects in Phase 1a Trial of CDX-6114
firstwordpharma
July 10, 2018Codexis, Inc.?(NASDAQ:CDXS), a leading protein engineering company, announces that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114 -
TxCell Exercises in-License Option to the University of British Columbia's Intellectual Property Rights of the HLA-A2 CAR-Treg Program
firstwordpharma
July 10, 2018TxCell SA?(Paris:TXCL) (FR0010127662 – TXCL),?a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation,
Pharma Sources Insight January 2025
